pharmaphorum

AUGUST 25, 2022

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK’s first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio’s CAR-T therapy Abecma (idecabtagene vicleucel) and J&J/Legend Biotech’s CAR-T Carvykti (ciltacabtagene autoleucel).

FDA 95

FDA Marketing Safety Patients 95

pharmaphorum

JULY 25, 2022

.” GSK’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) was the first BCMA-targeting drug to reach the market in 2020, and has since been joined by Carvykti as well as Bristol-Myers Squibb and bluebird bio rival CAR-T therapy Abecma (idecabtagene vicleucel).

Medicine 52

Medicine FDA Recruitment Patients 52

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Medicine 52

pharmaphorum

NOVEMBER 28, 2022

Owkin in particular has bagged some high-profile, high-price tag development deals with the likes of Bristol-Myers Squibb and Sanofi. A number of companies have sprung up offering AI models to help pharma companies with drug discovery over the past few years.

Training 70

Training Medical Pharma Healthcare 70